Diabetes/Nutrition/Obesity Flashcards
Describe the incidence, etiology and risk factors for pregestational diabetes in pregnancy
Incidence: 14% of diabetes in pregnancy is pregestational (86% GDM)
High risk for pregestational diabetes:
- Overweight or Obesity (BMI >25; BMI >23 in Asian women) +
- Age > 40 years
- Previous history of GDM
- Hypertension (>140/90 or on antiHTNs)
- Prior macrosomia (> 4000 g)
- Prior IUFD or fetal congenital anomalies
- Physical inactivity
- First-degree relative with diabetes
- High-risk race or ethnicity (African, Native, or Asian Americans, Latino, or Pacific Islander)
- HDL < 35 mg/dl, triglycerides >250 mg/dl
- Polycystic ovarian syndrome or symptom of insulin resistance (ie acanthosis nigricans)
- Hx of cardiovascular disease
- HA1C = 5.7 or higher
Describe the incidence, etiology and risk factors for gestational diabetes
Risk factors:
- Hispanic, African American, Native American, and Asian or Pacific Islander races
- Age > 40
- BMI > 25
- Prior history of GDM, glycosuria or impaired carbohydrate metabolism
- Strong family history of type 2 diabetes (two first-degree relatives)
- Prior history of stillbirth, infant with congenital anomalies, or macrosomia
Acceptable tests for assessing pregestational diabetes:
- Fasting plasma glucose (diagnostic ≥126 mg/dl)
- Fasting = no caloric intake for at least 8 h
- Hemoglobin A1c (diagnostic ≥ 6.5%)
- 2 h OGT after 75 gm glucose load OR random plasma glucose (diagnostic ≥ 200 mg/dl) in patient with classic symptoms
- A 3-hour test has never been validated in early pregnancy
- If first trimester test negative in high risk patient, screen for GDM at 24-28 weeks
Pathyphysiology of GDM
“Early type 2 diabetes”
Hormones synthesized by the enlarging placenta (later half of pregnancy) and pro-inflammatory cytokines → increased insulin resistance → parental ß-cells can’t keep up with enough insulin secretion
Hormones involved:
- Human placental lactogen (aka chorionic growth hormone)
- Human placental growth hormone
- Progesterone
- Leptin
- TNFα
- Cortisol
Screening methods to identify GDM, including advantages and disadvantages
- Screen at 24 - 28 weeks
-
ONE-STEP method (recommended by WHO):
- 75-g, 2 hour OGTT
- Diagnosis of GDM : If one abnormal value
- Fasting ≥ 92 mg/dl
- One hour ≥180 mg/dl
- Two hour ≥153 mg/dl
- May potentially overdiagnose, but less likely to underdiagnose
-
TWO-STEP method (recommended by ACOG)
-
Screening
- 1 hour, 50gm glucose challenge
- Value > 135 or 140 mg/dl → require diagnostic test
- Depending on which end of the range you use, you might miss cases or do unnecessary 3-hour OGTTs
-
Diagnosis (Carpenter and Coustan criteria)
- 2 or more abnormal values on 3 hour, 100gm glucose tolerance test
- Fasting > 95 mg/dl
- 1h> 180 mg/dl
- 2h> 155 mg/dl
- 3h> 140 mg/dl
- 2 or more abnormal values on 3 hour, 100gm glucose tolerance test
-
Screening
Describe risks to the fetus in all types of diabetes
- Increased risk of congenital anomalies: esp cardiac and CNS malformations
- HA1C < 6.5% reduces risk if pregestational
- Macrosomia (birth weight > 4000 gms)
- Birth trauma (shoulder dystocia, nerve palsies)
- Respiratory distress syndrome
- Hypoglycemia
- Hyperbilirubinemia
- Perinatal mortality
- Long term: Increased risk of obesity, type 2 diabetes
Describe the role of fetal surveillance in the management of pregnancies complicated by all types of diabetes
- Serial U/S assessments of fetal growth q4-6 wks:
- EFW
- AC (most predictive of macrosomia)
- HC/AC ratio
- Fetal movement counting - daily starting at 28 weeks
- If comorbidities (CHTN, nephropathy ) → consider doppler u/s at 28 weeks
- A1 GDM
- NSTs starting at term (some say not necessary)
- A2 GDM and beyond
- NST/BPP 2x/week starting at 32 weeks
Describe strategies for the antepartum management of diabetes (all types) in pregnancy
- Office visits q 1-2 weeks
- Weekly after 36 weeks
- Maternal assessments
- Glucose control
- Urinary ketones and albumin
- Blood pressure
- Timing of delivery
- Less than 39 weeks with poor or undocumented control → establish lung maturity with amniocentesis (presence of PG)
- A1 not be before 39 weeks of gestation, unless otherwise indicated. Expectant management up to 40 6/7 weeks.
- A2 (well controlled) - 39 0/7 to 39 6/7 weeks
- Offer cesarian if EFW is > 4500 g
Blood glucose goals during pregnancy
- Before breakfast: 60-90 mg/dl
- Before lunch, dinner, bedtime snack: 60-105 mg/dl
- 1 hour post prandial: ≤ 130 mg/dl
- 2 hours post prandial: ≤ 120 mg/dl
- 2:00 to 6:00 AM: > 60 mg/dl
Medications for GDM
-
Insulin: Does not cross placenta → drug of choice
- Typically initiated if fasting or postprandial BG not controlled by diet, activity
- Start with low dose and adjust as needed
- 0.7-1 unit/kg/day in divided doses
- Markedly increased requirements 3rd trimester
-
Oral drugs: Crosses placenta → long term effects unknown
- Glyburide increasingly used for GDM not controlled with diet: Start with 2.5 mg BID
- Metformin not as well-studied in pregnancy but is also being used
How often should blood glucose be monitored?
- No great evidence
- General consensus: 4x/day
- Fasting
- After each meal (1 to 2 hours after)
Exercise recommendations for GDM
(ACOG)
- Aim for 30 minutes of moderate-intensity aerobic exercise at least 5 days a week
- Or a minimum of 150 minutes per week.
Discuss postpartum screening for diabetes
- Scree at 4–12 weeks postpartum
- Use non-pregnancy cutoffs
- 75 g, 2 hour GTT
- Normal: < 140 mg/dl
- Impaired: 140-199 mg/dl
- Diabetes: ≥ 200 mg/dl
- If impaired fasting glucose, IGT, or diabetes → refer for preventive or medical therapy.
- Repeat testing every 1–3 years for women who had normal postpartum screening test results
Classification of types of diabetes
(according to White)
- A1 - GDM, managed by diet and lifestyle
- A2 - GDM, managed by insulin or glyburide
These are just FYI (Kim’s slide):
- B - < 10 years duration
- C - 10 - 19 years duration
- D - > 20 years duration, presence of vascular disease
- R - Retinopathy
- F - Nephropathy
- H - Heart disease
- T - s/p transplantation
Discuss obstetrical complications of diabetes in pregnancy, including:
- Macrosomia
- Shoulder dystocia
- Operative delivery
- Postpartum hemorrhage
- Macrosomia
- EFW not very accurate. Needs to be > 4800 g to have 50% chance of predicting BW > 4500 g
- Shoulder dystocia
- Higher risk due to macrosomia and also the adiposity of baby with insulin-dependent parent
- Operative delivery
- Offer cesarean if EFW > 4500 g
- Postpartum hemorrhage
Describe the implications of GDM on future health for both the parent and infant
- Parent
- GDM is biggest risk factor for Type 2 DM
- 60% within 5 years develop it.
- Decreases risk:
- Breastfeeding (longer = less likely)
- Return to prepregnant weight
- Group/telemedicine support
- GDM + family hx of type 2 → risk for developing metabolic syndrome
- GDM is biggest risk factor for Type 2 DM
- Infant
- Risk for being overweight/obese, type 2 DM, metabolic syndrome
Scope of practice for CNM/WHNP when caring for women with a pregnancy complicated by diabetes or obesity
- GDM commonly managed by CNMs/NPs/PAs
- MD consult for pharm therapy:
- Abnormal fasting glucose levels
- If < 80– 90% of postprandial values meet glucose target levels
Describe risks to the fetus and the role of fetal surveillance in the management of pregnancies complicated by obesity
Risk to fetus:
- Increased breastfeeding difficulties
- Increased risk of macrosomia
- Increased risk of metabolic syndrome, diabetes, obesity later in life (epigenetic effects)